Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 71

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 71
---
12,449 Deferred income tax benefit(11,152)(13,597)Inventory valuation write-down1,467 2,022 Payment of contingent consideration(4,900)— Other noncash adjustments, net3,779 4,601 Changes in operating assets and liabilities:Accounts receivable1,246 (8,339)Inventories9,618 8,015 Prepaid expenses and other assets4,870 (6,789)Accrued product returns and rebates12,211 20,845 Accounts payable and other liabilities(2,547)(2,770)Net cash provided by operating activities89,134 74,025 Cash flows from investing activitiesPurchases of marketable securities(259,113)(317,680)Maturities of marketable securities266,605 217,774 Purchases of property and equipment(782)(312)Net cash provided by (used in) investing activities6,710 (100,218)Cash flows from financing activitiesProceeds from issuance of common stock5,318 4,569 Employee taxes paid related to net share settlement of equity awards(3,387)(1,341)Payment of contingent consideration(22,395)— Net cash provided by (used in) financing activities(20,464)3,228 Net change in cash and cash equivalents75,380 (22,965)Cash and cash equivalents at beginning of year69,331 75,054 Cash and cash equivalents at end of period$144,711 $52,089 Supplemental cash flow informationCash paid for income taxes$12,697 $20,762 

See accompanying notes.

8

Supernus Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

1.    Business Organization

Supernus Pharmaceuticals, Inc. (the Company, see Consolidation in Note 2, Summary of Significant Accounting Policies) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel CNS product candidates including new potential treatments for